Medically reviewed by Prof. Dr. Zahid Mahmood, MBBS, FCPS — General, Laparoscopic & Laser Surgeon, Lahore.
Pancreatic cancer begins when abnormal cells grow uncontrollably in the pancreas. The commonest type is pancreatic ductal adenocarcinoma. Early disease often causes few or vague symptoms, which means many patients are diagnosed only after the tumour has grown or spread.
Jaundice, unexplained weight loss, persistent upper-abdominal or back pain, loss of appetite and newly developing diabetes can be warning signs. These symptoms have many non-cancerous causes, but they deserve prompt medical assessment—especially when persistent, progressive or occurring together.
What is the pancreas?
The pancreas is a gland behind the stomach. Its broad right side, called the head, lies beside the duodenum; the body crosses the upper abdomen; and the tail extends toward the spleen.
The pancreas has two major functions:
- Digestive function: it produces enzymes that help break down fat, protein and carbohydrate.
- Hormonal function: it produces insulin and other hormones that regulate blood glucose.
Tumours in the pancreatic head can block the bile duct and cause jaundice relatively early. Tumours in the body or tail may grow silently before producing pain or weight loss.
Types of pancreatic cancer
More than 85% of pancreatic cancers are ductal adenocarcinomas, arising from cells lining the pancreatic ducts. This guide mainly discusses that type.
Less common pancreatic tumours include neuroendocrine tumours, acinar-cell carcinoma, solid pseudopapillary tumours and cancers arising within certain mucinous cysts. Their behaviour and treatment can be very different, so the exact pathological diagnosis matters.
What causes pancreatic cancer?
Most patients have no single identifiable cause. Risk rises with age and is influenced by genetic, medical and lifestyle factors. Important associations include:
- Cigarette smoking
- Chronic pancreatitis, particularly hereditary pancreatitis
- Obesity and physical inactivity
- Long-standing diabetes—and, in some people, newly developing diabetes caused by the cancer
- A strong family history of pancreatic cancer
- Inherited variants involving genes such as BRCA1, BRCA2, PALB2, CDKN2A or mismatch-repair genes
- Peutz–Jeghers syndrome and certain other inherited cancer syndromes
- Some pancreatic cysts, especially main-duct IPMN or mucinous cystic neoplasms with high-risk features
Having a risk factor does not mean a person will develop cancer, and many patients have no known risk factors.
Symptoms of pancreatic cancer
Possible symptoms include:
- Jaundice: yellow skin or eyes, dark urine, pale stools and itching
- Persistent pain in the upper abdomen, sometimes spreading to the back
- Unexplained weight loss and loss of muscle
- Reduced appetite, nausea or feeling full quickly
- Indigestion, bloating or changes in bowel habit
- Pale, greasy, floating or difficult-to-flush stools caused by poor fat digestion
- New diabetes, or previously controlled diabetes becoming unexpectedly difficult to manage
- Fatigue and weakness
- An unexplained attack of acute pancreatitis
- A blood clot in the leg or lung without an obvious reason
No symptom proves pancreatic cancer. Gallstones, hepatitis, pancreatitis, peptic disease and many other conditions can cause similar problems.
Warning signs that need urgent assessment
Arrange prompt medical review for:
- New, unexplained jaundice
- Progressive, unexplained weight loss
- Persistent upper-abdominal pain radiating to the back
- New diabetes after age 50 accompanied by weight loss or upper-abdominal symptoms
- Pale greasy stools, dark urine or persistent itching
- Unexplained pancreatitis, especially in an older adult
Go to an emergency department for jaundice with fever or shaking chills, confusion, fainting, persistent vomiting, severe dehydration, vomiting blood, black stools, sudden shortness of breath or a painful swollen leg.
Can pancreatic cancer be detected early?
There is no reliable screening test recommended for the general population. CA 19-9 is not suitable for screening because it can be normal in pancreatic cancer, raised by benign jaundice or inflammation, and is not produced by some people.
Specialist surveillance with MRI/MRCP, endoscopic ultrasound or other imaging may be offered to selected people with a strong inherited risk. Anyone with several close relatives affected or a known cancer-predisposition gene should discuss genetic counselling and specialist surveillance rather than arranging unstructured scans.
How is pancreatic cancer investigated?
Evaluation begins with the history, examination and blood tests. The clinician checks for jaundice, weight loss, an enlarged gallbladder, abdominal tenderness, liver enlargement, fluid in the abdomen and signs of spread.
Blood tests may include:
- Liver function and bilirubin
- Full blood count, kidney function, clotting and nutritional markers
- Blood glucose or HbA1c
- CA 19-9 as a baseline tumour marker after interpreting any bile-duct obstruction
A CA 19-9 result cannot confirm or exclude cancer by itself. It may help monitor response or recurrence when initially elevated.
Ultrasound and pancreatic-protocol CT
Ultrasound is often the first test for jaundice and can show dilated bile ducts, gallstones, liver lesions or sometimes a pancreatic mass. A normal or unclear ultrasound does not exclude pancreatic cancer.
A pancreatic-protocol contrast CT is the central imaging test. It identifies the tumour, its relationship to major blood vessels, possible lymph nodes and spread to the liver, lungs or peritoneum. When obstructive jaundice suggests pancreatic cancer, guidance recommends obtaining the pancreatic CT before draining the bile duct whenever the patient is stable enough.
MRI, endoscopic ultrasound and PET-CT
- MRI/MRCP: provides detailed views of the pancreatic and bile ducts and can clarify small liver or cystic lesions.
- Endoscopic ultrasound (EUS): places an ultrasound probe close to the pancreas through the stomach or duodenum and allows needle biopsy.
- FDG-PET/CT: may be used in apparently localised cancer before surgery or other cancer treatment to detect hidden spread.
- Staging laparoscopy: may find tiny liver or peritoneal deposits not visible on scans in selected patients being considered for major surgery.
Is a biopsy always needed?
Tissue confirmation is needed before chemotherapy, radiotherapy or treatment of unresectable disease. EUS-guided biopsy is commonly used because it samples the mass through the stomach or duodenum.
For a clearly resectable pancreatic mass with highly characteristic imaging, surgery may sometimes proceed without a preoperative biopsy after multidisciplinary discussion. A negative or inconclusive biopsy does not automatically rule out cancer if imaging remains strongly suspicious.
How is pancreatic cancer staged?
Formal staging considers tumour size and local extension, lymph nodes and distant metastases. For treatment planning, the multidisciplinary team often uses four practical groups:
- Resectable: the tumour can be completely removed without unacceptable involvement of critical vessels.
- Borderline resectable: limited involvement of nearby vessels makes immediate surgery uncertain; treatment may shrink or stabilise the tumour first.
- Locally advanced unresectable: the tumour involves major local vessels or structures but has not spread to distant organs.
- Metastatic: cancer has spread, commonly to the liver, peritoneum, lungs or distant lymph nodes.
Resectability should be decided by an experienced pancreatic multidisciplinary team. A tumour considered inoperable in one setting may warrant review at a specialist high-volume centre.
Treatment planning
Treatment depends on stage, tumour biology, symptoms, overall fitness and the patient’s priorities. Care should be coordinated by a team including pancreatic surgeons, oncologists, gastroenterologists, radiologists, pathologists, dietitians, pain and palliative-care specialists.
Inherited genetic testing and molecular testing of tumour tissue or blood may be recommended. Results can occasionally identify a targeted treatment, immunotherapy option or an inherited risk relevant to close family members.
Surgery for pancreatic cancer
Surgery offers the main chance of long-term cure when the tumour is localised and removable. It is a major operation and should be performed in a specialist centre that regularly manages pancreatic cancer.
Whipple operation
A pancreatoduodenectomy, commonly called the Whipple operation, is used for cancer in the pancreatic head. It removes the head of the pancreas, duodenum, gallbladder, lower bile duct and nearby lymph nodes; sometimes part of the stomach is also removed. The surgeon then reconnects the remaining pancreas, bile duct and stomach or duodenum to the intestine.
Distal pancreatectomy
Tumours in the pancreatic body or tail are treated with removal of that portion, usually together with the spleen. Splenectomy requires specific vaccinations and infection-prevention advice.
Total pancreatectomy
Removal of the entire pancreas is reserved for selected multifocal or extensive disease. It causes permanent insulin-dependent diabetes and complete pancreatic enzyme deficiency.
Risks and recovery after pancreatic surgery
Possible complications include bleeding, infection, chest problems, blood clots, delayed stomach emptying, bile leakage and leakage from the pancreatic connection, called a pancreatic fistula. Some patients develop diabetes or require lifelong pancreatic enzyme capsules.
Recovery takes weeks to months. Early walking, breathing exercises and gradually increasing nutrition are important. Small frequent meals and pancreatic enzyme replacement may improve digestion, weight and strength.
Chemotherapy
Most patients who undergo successful resection are offered chemotherapy after recovery to destroy microscopic cancer cells and reduce recurrence risk. Fit patients may receive combination treatment such as modified FOLFIRINOX; other regimens are used when this is unsuitable.
For borderline resectable cancer, chemotherapy—with or without radiotherapy—may be given before surgery. For locally advanced or metastatic disease, systemic chemotherapy can slow cancer growth, reduce symptoms and prolong life. Common combinations include FOLFIRINOX-type treatment or gemcitabine-based therapy.
The oncologist selects treatment according to performance status, liver function, other illnesses, tumour genetics and patient preference. Side effects can include fatigue, nausea, infection risk, diarrhoea, mouth soreness, altered sensation and hair changes, but supportive medicines and dose adjustments help many patients.
Radiotherapy and targeted treatments
Radiotherapy is not required for every patient. It may be considered with chemotherapy for selected locally advanced or borderline tumours, or to relieve pain and control local symptoms.
A small subgroup has tumour changes that may respond to targeted drugs or immunotherapy—for example, certain BRCA/PALB2-related cancers, mismatch-repair deficiency, NTRK fusion or other actionable alterations. This is why genetic and molecular testing can matter.
Relieving jaundice
A tumour in the pancreatic head can block the bile duct. ERCP can place a stent across the blockage to drain bile, relieve itching and treat or prevent infection. A radiological drain may be used if endoscopic access is unsuccessful.
Routine stenting before prompt surgery is not necessary for every stable patient with resectable disease because it can introduce infection. Drainage is important when cholangitis is present, jaundice is severe, surgery will be delayed or the patient needs optimisation or preoperative treatment.
Pain, nutrition and pancreatic enzymes
Good supportive care should begin at diagnosis, alongside cancer-directed treatment:
- Pain: regular analgesia can be escalated appropriately. A coeliac plexus nerve block may help difficult upper-abdominal or back pain.
- Pancreatic enzymes: pancreatin capsules taken with meals improve digestion when stools are greasy or weight is falling, and are routinely considered after pancreatic surgery or in unresectable disease.
- Nutrition: a specialist dietitian can recommend calorie- and protein-rich foods, supplements and enzyme adjustment.
- Diabetes: glucose should be monitored and treated with tablets or insulin according to pancreatic function.
- Stomach or duodenal blockage: an endoscopic stent or surgical bypass may restore eating.
Palliative care
Palliative care is not limited to the final days of life. It can begin early to control pain, nausea, fatigue, anxiety, jaundice, digestive problems and family stress while the patient continues chemotherapy or other treatment. The aim is better comfort, function and quality of life.
Can pancreatic cancer be prevented?
There is no guaranteed prevention. Avoiding tobacco, maintaining a healthy weight, limiting alcohol and managing diabetes support general pancreatic health. People with hereditary pancreatitis, certain gene variants or a strong family history should seek genetic counselling and specialist surveillance.
Common questions
Is every pancreatic mass cancer?
No. Pancreatitis, benign cysts and some slow-growing tumours can resemble cancer. Pancreatic-protocol imaging and, when needed, EUS-guided biopsy establish the diagnosis.
Does normal CA 19-9 exclude pancreatic cancer?
No. Some cancers do not raise CA 19-9, and some people cannot produce it. Benign jaundice can also elevate it. The result must be interpreted with imaging and clinical findings.
Can pancreatic cancer be cured?
Cure is possible mainly when the tumour is localised, completely removed and treated with appropriate systemic therapy. Even after surgery, recurrence is possible, so follow-up is essential.
Can a person live without part of the pancreas?
Yes. Many people live with a smaller pancreas, although some need enzyme capsules or diabetes treatment. Removing the entire pancreas always requires lifelong insulin and enzymes.
Should family members be tested?
Not automatically. Genetic counselling usually begins with testing the affected patient. If an inherited pathogenic variant is found, targeted testing and surveillance may be offered to relatives.
Is a second opinion useful?
Yes, particularly about resectability or a major operation. Review by a specialist pancreatic multidisciplinary team can confirm staging and treatment options without necessarily delaying urgent care.
Key message
Pancreatic cancer may be silent early, but unexplained jaundice, progressive weight loss, persistent upper-abdominal or back pain and new diabetes with weight loss deserve prompt assessment. Pancreatic-protocol CT, specialist staging and multidisciplinary review determine whether surgery, chemotherapy, radiotherapy or symptom-focused treatment is appropriate. Early nutritional, pain and psychological support are essential at every stage.
Medical references
- O’Connell PR, McCaskie AW, Sayers RD, editors. Bailey & Love’s Short Practice of Surgery. 28th ed. Chapter 72: The pancreas, pp. 1281–1287.
- National Institute for Health and Care Excellence. Pancreatic cancer in adults: diagnosis and management (NG85). Last reviewed September 2025.
- National Cancer Institute. Pancreatic Cancer Treatment (PDQ®)—Patient Version. Updated 2026.
- Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395:2008–2020.
This article provides general education and does not replace an examination or individual cancer advice. Seek urgent care for jaundice with fever, confusion, persistent vomiting, fainting, vomiting blood, black stools or sudden breathing difficulty.